New Federal Incentives for Diversity in Clinical Trials

被引：42

作者：

Hwang, Thomas J. ^{[1
,2
]}

Brawley, Otis W. ^{[3
,4
]}

机构：

[1] Brigham & Womens Hosp, Div Urol Surg, 75 Francis St, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Canc Innovat & Regulat Initiat, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[3] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[4] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2022年 / 387卷 / 15期

关键词：

D O I：

10.1056/NEJMp2209043

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

New Federal Incentives for Diversity in Trials Recent House legislation would codify recommendations that trial sponsors design diversity plans for enrollment, but it does not provide a mechanism for remedying inadequate progress.

引用

页码：1347 / 1349

页数：3

共 4 条

[1]

[Anonymous], 2020, GAO-20-251

[2]

BibbinsDomingo K., 2022, IMPROVING REPRESENTA

[3]

Food and Drug Administration, 2022, DIV PLANS IMPR ENR P

[4] Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018 [J].

Loree, Jonathan M. ;

Anand, Seerat ;

Dasari, Arvind ;

Unger, Joseph M. ;

Gothwal, Anirudh ;

Ellis, Lee M. ;

Varadhachary, Gauri ;

Kopetz, Scott ;

Overman, Michael J. ;

Raghav, Kanwal .

JAMA ONCOLOGY, 2019, 5 (10)

← 1 →